Puma Biotechnology, Inc. (PBYI)

10.10 -0.42 (-3.94%) USD  |  NASDAQ  |  Oct 16, 12:04
More

Puma Biotechnology SG&A Expense (TTM) : 71.17M for June 30, 2026

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2010. Start Trial.
Date Value
June 30, 2026 71.17M
March 31, 2026 71.67M
December 31, 2025 70.85M
September 30, 2025 69.09M
June 30, 2025 69.09M
March 31, 2025 76.02M
December 31, 2024 80.16M
September 30, 2024 83.72M
June 30, 2024 89.71M
March 31, 2024 89.20M
December 31, 2023 89.93M
September 30, 2023 94.79M
June 30, 2023 95.95M
March 31, 2023 92.06M
December 31, 2022 89.98M
September 30, 2022 87.44M
June 30, 2022 89.56M
March 31, 2022 108.40M
December 31, 2021 116.23M
September 30, 2021 122.53M
June 30, 2021 126.05M
March 31, 2021 115.98M
December 31, 2020 118.68M
September 30, 2020 121.08M
June 30, 2020 122.89M
Date Value
March 31, 2020 127.07M
December 31, 2019 141.64M
September 30, 2019 151.44M
June 30, 2019 148.54M
March 31, 2019 155.14M
December 31, 2018 146.24M
September 30, 2018 136.14M
June 30, 2018 140.13M
March 31, 2018 124.92M
December 31, 2017 106.72M
September 30, 2017 92.32M
June 30, 2017 73.85M
March 31, 2017 61.19M
December 31, 2016 53.83M
September 30, 2016 46.93M
June 30, 2016 41.71M
March 31, 2016 34.98M
December 31, 2015 31.81M
September 30, 2015 30.31M
June 30, 2015 25.37M
March 31, 2015 23.74M
December 31, 2014 19.40M
September 30, 2014 14.28M
June 30, 2014 12.68M
March 31, 2014 11.04M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Anika Therapeutics, Inc. 52.67M
Arcutis Biotherapeutics, Inc. 297.60M
ACADIA Pharmaceuticals, Inc. 620.29M
Alnylam Pharmaceuticals, Inc. 1.318B
Savara, Inc. 56.71M